Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Allergan Inc.
Current Parent Company: AbbVie
Parent at the Time of the Penalty Announcement:  subscribe to see this data field
Recap of Ownership Changes:  subscribe to see this data field
Penalty: $30,000,000
Year: 2022
Date: August 5, 2022
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Allergan agreed to pay $30 million to settle end-payor multi-district litigation alleging it acted to block a generic version of its Restasis dry-eye medication.
Level of Government: federal
Action Type: private litigation
Court: Eastern District of New York
Civil or Criminal Case: civil
Case ID: 1:18md2819
Case Name: In Re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: Illinois
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.